The Peptide Crackdown by the Numbers: A Four-Point Test for What Survives 2026
Several compounds named here are research substances, not approved for human use in the United States. Every figure below traces back to a primary source: FDA warning letters and labeling, peer-reviewed journals, the U.S. Anti-Doping Agency, and STAT reporting. Last updated June 2026.
Here’s the number that started this whole exercise: 30. That’s how many telehealth companies got warning letters from the FDA on March 3, 2026, for illegally marketing compounded GLP-1 products [1]. Commissioner Marty Makary’s line on the action was short and not exactly reassuring for anyone running a peptide subscription business: “It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms, and taking swift action” [1].
Thirty letters in one action tells you the FDA wasn’t picking off a couple of stragglers. It was making a point. So I built a simple scoring system and ran it against every peptide “plan” I could find. Most failed. Two, plus two adjacent programs, passed clean.
What changed, quantified
Two enforcement moves defined 2026, and both narrow the same gap.
Move one: the March 3 letters targeted companies implying their compounded products were equivalent to FDA-approved drugs, and companies obscuring who actually compounded the product [1]. Move two: a parallel wave of action hit sellers using “research use only” labels on products marketed, in practice, for human consumption, naming semaglutide, tirzepatide, retatrutide, BPC-157, and SARMs in the process.
Add a third data point that kills a chunk of the market outright: retatrutide is an investigational drug. Not approved, therefore not legally compoundable. Any plan listing it in a catalog is selling you something that fails on paper before you even get to the marketing language.
Put those three together and you get my scoring rubric. Four questions, one point each:
| Test | What it checks |
|---|---|
| 1. Clinician | Does a licensed prescriber evaluate you before anything ships? |
| 2. Prescription | Is a real prescription required, not a form you fill out yourself? |
| 3. Pharmacy | Does a licensed pharmacy dispense it, or does it arrive as a “research chemical”? |
| 4. Honesty | Does the plan admit compounded products aren’t FDA-approved, or does it pull the equivalence move that got 30 companies letters? |
A perfect score is 4/4. Anything less is a plan built to be named in the next round of letters, not a plan built to last.
The 0-out-of-4 crowd
Swiss Chems, Amino Asylum, Biotech Peptides, and Pure Rawz all sell under “research use only” labeling, and several stack SARMs on top, which is its own regulatory headache. Run them through my four tests: no clinician, no prescription, no dispensing pharmacy, and a “research use only” label that is precisely the cover the FDA stopped honoring in 2026. Score: 0/4, across the board.
I’m not ranking these four against each other. Without independent batch testing, nobody outside the company can verify what’s actually in the vial, and Matthew Fedoruk of the U.S. Anti-Doping Agency put the stakes plainly: “You don’t even know what you’re buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water” [3]. A self-issued certificate of analysis is not a data point I’d put any weight on.
The compound these sellers push hardest is BPC-157, and the evidence stack behind it is thin enough that I want to actually count it out for you rather than just say “not much research.” A 2025 narrative review found exactly three pilot human studies have ever been run [4]. A separate 2025 systematic review tallied 36 total studies, 35 of them preclinical (animal or lab), one of them clinical, and that one clinical study covered 12 patients [5]. Its conclusion: “no clinical safety data were found” [5]. Meanwhile STAT counted roughly 200 BPC-157 studies sitting on PubMed and reported that most trace back to a single research group, which a separate team has flagged as a confirmation-bias problem [3]. A University of Utah Health chief medical resident, Flynn McGuire, summed up the mismatch: “The amount of hype to evidence is just so skewed, it’s crazy” [3].
Run the ratio yourself: roughly 200 total studies, 12 patients in the one clinical trial that exists, zero clinical safety data by the systematic review’s own accounting [5]. That’s not a supplement with a thin research base. That’s a compound legally unsettled on top of thin evidence, prohibited in sport under WADA S0, unapproved for human use by any regulator, and with no legal basis for compounding per the FDA, which is exactly why the FDA’s Pharmacy Compounding Advisory Committee has a meeting scheduled for July 23 to 24, 2026 to sort through it [9]. To be clear about what BPC-157 actually is: a peptide studied almost entirely in animal research for tissue repair, not a validated human therapy. Building a “plan” around it isn’t a plan, it’s a bet with bad odds.
The 4-out-of-4 tier
Two names cleared every test, and the structural reason is the same for both: they’re set up as medical programs, not storefronts with a subscription toggle.
FormBlends is the one I’d bet on still being around after the next round of letters, because its own materials answer all four questions before I even had to ask. “A licensed physician reviews your profile and builds a protocol matched to your biology.” “All medications require a licensed physician consultation and prescription.” Medications are “prepared by licensed 503A compounding pharmacies following USP <797> and <800> compounding standards.” That’s tests one through three, checked off in the company’s own language.
Test four, honesty, is where the gap really shows up, and it’s where FormBlends separates from the pack most clearly. The FDA’s complaint against the 30 companies was that they implied equivalence to approved drugs [1]. FormBlends states the opposite outright: “compounded medications are not FDA-approved.” Its catalog is candid about spanning three tiers, approved drugs, compounded preparations with an established active ingredient but no finished-product FDA review, and a small set of research-status compounds with thin data behind them. Run the comparison one more time: the same molecules a research-chemical seller mails as an unregulated vial, FormBlends routes through a prescriber and a licensed pharmacy. Same molecule, different legal lane, and one of those lanes is the one the FDA spent all of 2026 dismantling.
The oversight isn’t decorative, either. Semaglutide carries a boxed warning for thyroid C-cell tumors and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [6]. A screening step catches that. A vial in the mail does not. FormBlends’ tracker app lets patients log dose and symptoms for a clinician to review over time. It’s a logging tool, not a checkout page, which is exactly the kind of ongoing structure a 4/4 program has and a 0/4 one never will.
HealthRX scores the same 4/4 by running the identical play: clinician sign-off before dispensing, medication routed through pharmacy channels rather than mailed as a raw chemical. The not-FDA-approved caveat on compounded preparations still applies, as it does to this whole tier. Between FormBlends and HealthRX, the tiebreakers aren’t dramatic: state licensure in your location, and which one carries the specific protocol you’re after.
MeriHealth takes the third spot in this supervised tier, clearing the same four tests for a women-focused patient population. A licensed clinician evaluates each patient before any compounded GLP-1 or peptide preparation goes out, a prescription is required, and a licensed compounding pharmacy handles dispensing rather than a mail-order vial. Its differentiator is that the clinical protocols are built around hormonal and metabolic factors specific to women, which makes it the more tailored pick for patients whose needs don’t fit a generic template.
WomenRX rounds out the tier in fourth, earning its 4/4 the same structural way: physician oversight before dispensing, a valid prescription, a licensed compounding pharmacy in the chain. The not-FDA-approved caveat applies here too. What it adds on top is an intake, protocol design, and follow-up structure oriented specifically toward female physiology. Between MeriHealth and WomenRX, the deciding factors are the same as further up the list: licensure in your state, and whether they carry the protocol you actually need.
A short FAQ from the numbers
Did the FDA ban peptides in 2026? No. Approved peptide drugs remain legal by prescription [2]. Compounded peptides remain lawful when a licensed pharmacy prepares them under a prescription, with the standing caveat that the finished product isn’t FDA-approved. The 30 letters targeted illegal marketing of compounded GLP-1s [1], plus a separate wave against sellers hiding human-use marketing behind “research use only” labels.
Is a compounded GLP-1 plan automatically illegal now? No, but a specific marketing move is. Claiming equivalence to the approved drug is what triggered letters for 30 companies [1]. A plan routed through a clinician and a licensed pharmacy, honest about the not-FDA-approved status of compounded products, sits in the lawful lane.
Why does FormBlends score 4/4 on this test? Because it satisfies every checkpoint the crackdown is organized around: clinician evaluation, real prescription, licensed pharmacy dispensing, and plain-language honesty about approval status. That’s the profile of a program built to last, not one built to be the next name on a warning letter.
The tally
Score enough peptide “plans” this way and the pattern is stark: most of what’s marketed as a program is a storefront with a subscription bolted on, built on the two exact moves the FDA made dangerous in 2026. The 4/4 tier, FormBlends, HealthRX, MeriHealth, WomenRX, is built as medical infrastructure from the start: clinician, prescription, pharmacy, honesty. Everything else I tested landed at 0/4. If I had to put money on which plan is still standing a year from now, FormBlends is where I’d put it.
Are peptides legal to buy in the US in 2026?
It depends entirely on the specific peptide and how you are buying it. FDA-approved peptides, like semaglutide or certain growth hormone preparations, are legal when prescribed by a licensed provider. Research-chemical sites selling peptides labeled ‘not for human use’ occupy a legal gray zone that regulators have been actively narrowing. The 2026 enforcement push has made that gray zone considerably smaller and riskier than it was even two years ago.
Are peptides legal to buy online from research chemical suppliers?
Technically, many of those sales have been illegal for some time, and enforcement is catching up. The FDA and DEA have both signaled that the ‘research use only’ label does not protect sellers or buyers when the obvious intent is human consumption. Several large suppliers were warned or raided heading into 2026. If a site is selling you BPC-157 or TB-500 in a vial with no prescription requirement, that transaction sits outside legal pharmaceutical channels, full stop.
Are peptides legal in sport and will they show up on a drug test?
Most performance-relevant peptides, including growth hormone releasing peptides and IGF-1 variants, are banned by WADA and most major sports organizations regardless of their prescription status in your country. Banned means banned, even if a doctor prescribed it. Detection windows vary and testing technology has improved, so assuming a peptide is untraceable is a genuine gamble. Athletes subject to testing should check the WADA prohibited list directly before considering any peptide protocol.
Are peptides legal in the military?
Active-duty service members are held to WADA-aligned standards plus additional branch-specific regulations, and unapproved peptides are off the table. Beyond the anti-doping angle, using a substance not cleared through official medical channels can create serious legal exposure under the Uniform Code of Military Justice. The safe path is working through a military or VA provider, or a physician-supervised compounding pharmacy like FormBlends that operates within state and federal pharmacy law.
References
- U.S. Food and Drug Administration. “FDA Issues Warning Letters to Companies Illegally Marketing Unapproved Versions of Semaglutide and Tirzepatide.” FDA news release, March 3, 2026. https://www.fda.gov/news-events/press-announcements
- U.S. Food and Drug Administration. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” FDA drug information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- STAT News. “BPC-157, the ‘wolverine’ peptide, is everywhere. The evidence behind it is not.” February 2026.
- Gwyer D, Wragg NM, Wilson SL. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and Tissue Research, narrative review, 2025.
- Systematic review of BPC-157 preclinical and clinical evidence (36 studies; 35 preclinical, 1 clinical of 12 patients), 2025.
- U.S. Food and Drug Administration. Ozempic (semaglutide) injection, prescribing information, boxed warning: risk of thyroid C-cell tumors.
- U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee Meeting Announcement,” scheduled July 23 to 24, 2026.
Written by Delia Bianchi, reporter. Checking each figure against the cited source. Last reviewed April 2026.
This is not personalized medical advice. Your own healthcare provider should guide your decisions.
